Susan L Dalrymple

发表

Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay

J. Isaacs, H. Hammers, W. Brennen, 2016, Oncotarget.

Detection and Quantification of the Evolution Dynamics of Apoptosis Using the PET Voltage Sensor 18F-Fluorobenzyl Triphenyl Phosphonium

R. Dannals, H. Ravert, J. Frost, 2009, Journal of Nuclear Medicine.

Prostate cancer androgen receptor activity dictates efficacy of Bipolar Androgen Therapy

Elizabeth A. Thompson, J. Luo, Jun Luo, 2022, medRxiv.

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

P. Nelson, Jianfeng Xu, W. Isaacs, 2021, JCI insight.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation

R. Hales, M. Hedayati, T. DeWeese, 2016, Clinical Cancer Research.

Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

C. Drake, A. D. De Marzo, J. Isaacs, 2009, Proceedings of the National Academy of Sciences of the United States of America.

Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors

P. Nelson, Jianfeng Xu, W. Isaacs, 2020, Oncogene.

Polo-like kinase-1 Inhibitors and the Antiandrogen Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling

M. Erlander, M. Yaffe, Jun Luo, 2022, bioRxiv.

The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

A. DeMarzo, J. Isaacs, A. Meeker, 2008, Cancer research.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models

L. Sokoll, J. Isaacs, D. Rosen, 2003, The Prostate.

Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells.

A. D. De Marzo, L. Sokoll, J. Isaacs, 2005, Cancer research.

Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.

J. Isaacs, D. V. Vander Griend, I. Litvinov, 2006, Cancer research.

PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor

J. Isaacs, Linzhao Cheng, I. Litvinov, 2006, The Prostate.

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

T. DeWeese, Haoming Zhou, J. Isaacs, 2012, The Prostate.

Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers

J. Isaacs, S. Denmeade, S. Dalrymple, 2006, Clinical Cancer Research.

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β‐catenin/TCF‐4 complex inhibition of c‐MYC transcription

J. Isaacs, L. Antony, S. Dalrymple, 2014, The Prostate.

Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells

J. Isaacs, S. Denmeade, L. Antony, 2009, Molecular Cancer Therapeutics.

The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

J. Isaacs, S. Dalrymple, Robin E. Becker, 2007, The Prostate.

Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

S. Christensen, G. Wilding, P. Nissen, 2012, Science Translational Medicine.

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

J. Karp, J. Isaacs, B. Simons, 2020, Molecular Cancer Therapeutics.

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.

Jun Luo, T. Leanderson, J. Isaacs, 2013, Cancer research.

Therapeutics , Targets , and Chemical Biology Tasquinimod Is an Allosteric Modulator of HDAC 4 Survival Signalingwithin theCompromisedCancerMicroenvironment

Jun Luo, T. Leanderson, J. Isaacs, 2013 .

Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

S. Christensen, G. Wilding, P. Nissen, 2012, Science Translational Medicine.

Third generation quinoline‐3‐carboxamide transcriptional disrupter of HDAC4, HIF‐1α, and MEF‐2 signaling for metastatic castration‐resistant prostate cancer

G. Perdew, S. Denmeade, W. Brennen, 2023, The Prostate.

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

T. Leanderson, J. Isaacs, Anders Olsson, 2014, Oncotarget.

Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer

D. Qian, J. B. Garrison, T. Leanderson, 2006, The Prostate.

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Elizabeth A. Thompson, Jun Luo, J. Hicks, 2022, The Journal of clinical investigation.